Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Failure of conventional radioiodine therapy of metastatic differentiated thyroid cancer could
be explained by:
- a suboptimal therapeutic approach, based on the administration of empirically fixed
amount of radioactivity
- the presence of lesions with impaired iodine uptake, due to the expression of specific
mutations
The study aims to:
- optimize therapy with pre-treatment 124-I blood and lesion dosimetry
- collect genetic data to check if specific mutations and/or miRNA over-expression could
be related to low iodine uptake or to radioresistance